Darolutamide (Nubeqa) is an advanced androgen receptor inhibitor used to treat metastatic hormone sensitive prostate cancer (mHSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC), helping to delay disease progression. It is taken with androgen deprivation therapy (ADT) and combined with chemotherapy for select patients, has been shown to improve survival while minimizing fatigue and cognitive issues.

Survival benefits of Darolutamide (Nubeqa)?

Dosing

Oral: 600 mg twice daily (two pills twice a day).

Administration

Administer with food. Swallow tablets whole.

Side Effects

Missed Dose

Administer as soon as possible prior to the next scheduled dose; do not take 2 doses at the same time to make up for a missed dose.

Reproductive Considerations

Males with female partners of reproductive potential should use effective contraception during darolutamide treatment and for 1 week after the last darolutamide dose.

Monitoring

Baseline CBC w diff, CMP and then every 6 months thereafter.
PSA every 3 months or as clinically indicated.

Mechanism of Action

Nubeqa blocks testosterone from attaching to the androgen receptors, helping to delay the cancer cell from growing.

Storage

Store Nubeqa at room temperature. Keep the bottle tightly closed after you first open it. Keep Nubeqa and all medicines out of reach of children.

Other Considerations

Tell your healthcare provider about all the medicines you take including prescription and over-the-counter medicines, vitamins, and herbal supplements. Nubeqa may affect the way other medicines work and other medicines may affect how Nubeqa works.

Notify MD of any new or worrisome side effects.